Tryngolza shows efficacy in severe hypertriglyceridemia as approval verdicts loom

This readout could boost Tryngolza’s standing in its potential rivalry with Arrowhead’s Redemplo in severe hypertriglyceridemia. This readout could boost Tryngolza’s standing in its potential rivalry with Arrowhead’s Redemplo in severe hypertriglyceridemia. Sobi and Ionis’ Tryngolza reduced the risk of acute pancreatitis by 85% in patients with severe hypertriglyceridemia during a pivotal Phase III programme. Credit: Korosi Francois-Zoltan / Shutterstock.com. Sobi has touted new efficacy results for Tryngolza (olezarsen) in severe hypertriglyceridemia, as the company and its commercial partner, Ionis Pharmaceuticals, gear up for the drug’s potential launch in the indication. Through a pooled subgroup analysis, which factored in results…

Source: Clinical Trials Arena